Form 4: Korro Bio Director Sells Shares Under 10b5-1 Plan

Korro Bio, Inc. director Jean Francois Formela reported the sale of common stock totaling 85,955 shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Jean Francois Formela, a director at Korro Bio, Inc., has reported the sale of common stock on July 2, 2026, and July 6, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on April 8, 2026.
• On July 2, 2026, 85,955 shares were sold at a weighted average price of $14.03, with individual sales ranging from $13.95 to $14.16.
• On July 6, 2026, an additional 817 shares were sold at a weighted average price of $13.96, with individual sales ranging from $13.95 to $14.05.
• The filing also details the disposal of 14,745 shares on July 2, 2026, and 8,506 shares on July 6, 2026, at similar weighted average prices.
• Beneficial ownership details indicate that some shares are held indirectly through Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., with Formela disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-defined Rule 10b5-1 plan, which is designed to avoid the appearance of insider trading based on material non-public information.

Negatives

• Director Jean Francois Formela sold a significant number of shares, indicating a reduction in direct beneficial ownership.

Risks

• The sale of shares by a director, even under a Rule 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, although the plan's existence mitigates this to some extent.
• Indirect beneficial ownership structures can add complexity to understanding the true extent of an insider's holdings and potential future sales.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5).
• The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
• The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage personal portfolios. The specific context of Korro Bio's stage of development and recent news would be crucial for a deeper analysis of this transaction's implications.

Stakeholder Impact

• Shareholders: May observe the sale as a reduction in insider confidence, though the Rule 10b5-1 plan mitigates this concern. The specific reasons for the sale (e.g., diversification, personal liquidity needs) are not disclosed.
• Management: The transaction is executed by a director, indicating a personal financial decision rather than a company-wide strategic move.
• Creditors: No direct impact is indicated by this filing.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Beneficial Ownership, Atlas Venture Fund